Xilio Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Xilio Therapeutics, Inc. (XLO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are XLO insiders buying or selling?
In the last 12 months, Xilio Therapeutics, Inc. insiders reported 1 open-market purchase ($44.0K) and 0 sales ($0) — net buying of $44.0K. Since October 2021, Trabud has recorded 15 Form 4 filings for XLO: 12 buys ($45.1M) and 3 sells ($12.2K).
Source: SEC EDGAR Form 4
Key Statistics (October 2021 – Mar 30, 2026)
Total Form 4 filings
15
SEC EDGAR
Insider filers
12
Insider buys (12)
$45.1M
Insider sells (3)
$12.2K
Insider sentiment
Net buyingNet insider flow of $45.1M in net buying since October 2021, and $44.0K in net buying over the last 12 months.
Recent XLO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | James Samuel Shannon | Director | Purchase | 5.0K | $8.79 | $44.0K | SEC ↗ |
| Jun 18, 2025 | James Samuel Shannon | Director | Purchase | 70.0K | $0.69 | $48.1K | SEC ↗ |
| Jun 18, 2025 | Rene Russo | PRESIDENT AND CEO | Purchase | 36.3K | $0.68 | $24.7K | SEC ↗ |
| Jan 3, 2025 | Christopher James Frankenfield | Chief Financial Officer | Sale | 7.0K | $0.98 | $6.8K | SEC ↗ |
| Jan 3, 2025 | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Sale | 1.8K | $0.98 | $1.8K | SEC ↗ |
| Dec 19, 2024 | GILEAD SCIENCES, INC. | 10% Owner | Purchase | 1.8M | $1.04 | $1.8M | SEC ↗ |
| Apr 3, 2024 | GILEAD SCIENCES, INC. | 10% Owner | Purchase | 485.3K | $0.76 | $368.8K | SEC ↗ |
| Jan 16, 2024 | Atlas Venture Fund XI, L.P. | 10% Owner | Sale | 4.2K | $0.85 | $3.6K | SEC ↗ |
| Dec 11, 2021 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Purchase | 42.5K | $9.66 | $410.2K | SEC ↗ |
| Nov 3, 2021 | SV7 Impact Medicine Fund LP | 10% Owner | Purchase | 625.0K | $16.00 | $10.0M | SEC ↗ |
| Oct 28, 2021 | Flynn James E | Other, 10% Owner | Purchase | 775.0K | $16.00 | $12.4M | SEC ↗ |
| Oct 26, 2021 | RiverVest Venture Fund IV, L.P. | 10% Owner | Purchase | 250.0K | $16.00 | $4.0M | SEC ↗ |
| Oct 26, 2021 | Rock Springs Capital Management LP | 10% Owner | Purchase | 500.0K | $16.00 | $8.0M | SEC ↗ |
| Oct 26, 2021 | BAY CITY CAPITAL LLC | 10% Owner | Purchase | 312.5K | $16.00 | $5.0M | SEC ↗ |
| Oct 26, 2021 | Atlas Venture Fund XI, L.P. | 10% Owner | Purchase | 187.5K | $16.00 | $3.0M | SEC ↗ |
Showing the 15 most recent of 15 Form 4 filings for Xilio Therapeutics, Inc..
Most active XLO insiders
- Atlas Venture Fund XI, L.P.2 filings
- GILEAD SCIENCES, INC.2 filings
- James Samuel Shannon2 filings
- Bain Capital Life Sciences Investors, LLC1 filing
- BAY CITY CAPITAL LLC1 filing
Ask anything about XLO insider activity
Use Trabud's AI agent to query Xilio Therapeutics, Inc.'s Form 4 history in plain English — "Show me XLO CEO purchases this year" or compare it against any other ticker.
Open the AI agentXLO insider trading FAQ
Are Xilio Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Xilio Therapeutics, Inc. insiders reported 1 open-market purchase ($44.0K) and 0 sales ($0) — net buying of $44.0K. Since October 2021, Trabud has recorded 15 Form 4 filings for XLO: 12 buys ($45.1M) and 3 sells ($12.2K). Over the full record that is net buying of $45.1M.
How many insiders trade XLO stock?
12 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Xilio Therapeutics, Inc.. The most recent filing was accepted on Mar 30, 2026.
Where does Trabud get XLO insider trading data?
All XLO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.